Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Palmér (Gothenburg, Sweden), J. Almquist (Gothenburg, Sweden), M. Hashemi (Gothenburg, Sweden), Z. Taib (Gothenburg, Sweden), S. Necander (Gothenburg, Sweden), K. Korsback (Gothenburg, Sweden), M. Aurell (Gothenburg, Sweden), S. Asimus (Gothenburg, Sweden), S. Delaney (Gothenburg, Sweden), K. Pardali (Gothenburg, Sweden), P. Gustafson (Gothenburg, Sweden), T. Sethi (Gothenburg, Sweden), D. Keeling (Gothenburg, Sweden), I. Psallidas (Gothenburg, Sweden). Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis. 2278

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial Source: International Congress 2018 – Primary care management of respiratory conditions Year: 2018 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018 Year: 2018 Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial Source: Eur Respir J, 52 (2) 1800555; 10.1183/13993003.00555-2018 Year: 2018 Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies. Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Application of machine learning algorithms to predict loss of asthma control: A post-hoc analysis of INCONTRO study Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT) Source: International Congress 2017 – Many faces of asthma assessment Year: 2017 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD - a one-year follow-up randomised, controlled trial Source: Eur Respir J 2002; 20: Suppl. 38, 67s Year: 2002 Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021